Skip to main content
Erschienen in: Current Heart Failure Reports 2/2013

01.06.2013 | Management of Heart Failure (TE Meyer, Section Editor)

Treating Hypertension in Patients with Left Ventricular Dysfunction: Hitting the Fairway and Avoiding the Rough

verfasst von: Samuel W. Joffe, Robert A. Phillips

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is a major risk factor in the development of heart failure (HF), yet current guidelines do not specify a target blood pressure (BP) for patients with established systolic or diastolic left ventricular (LV) dysfunction. While no randomized controlled trial (RCT) has been conducted to specify the optimal blood pressure in these patients, numerous trials have demonstrated the benefits of certain classes of medications and treatment strategies in patients with HF. Important factors to consider in treating hypertension in patients with HF include the type of HF (reduced vs. preserved ejection fraction), the etiology (ischemic vs. nonischemic), the severity of symptoms if any, the baseline blood pressure, as well as a wide variety of patient-specific factors. This paper reviews current evidence to address the question, “What should be the blood pressure goal in patients with asymptomatic and symptomatic left ventricular dysfunction?” We suggest a target blood pressure of 120–140/70–90 mm Hg in most cases, with lower pressures generally preferable if tolerated.
Literatur
1.
Zurück zum Zitat Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis. 1955;1:33–42.PubMedCrossRef Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis. 1955;1:33–42.PubMedCrossRef
2.
Zurück zum Zitat Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure—the Framingham study. N Engl J Med. 1972;287:781–7.PubMedCrossRef Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure—the Framingham study. N Engl J Med. 1972;287:781–7.PubMedCrossRef
3.
Zurück zum Zitat Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 275(20):1557–62. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 275(20):1557–62.
4.
Zurück zum Zitat Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation. 2007;115(7):855–60.PubMedCrossRef Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation. 2007;115(7):855–60.PubMedCrossRef
5.
Zurück zum Zitat Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.PubMedCrossRef Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44.PubMedCrossRef
6.
Zurück zum Zitat Nigel S, Beckett NS, Ruth Peters R, Nigel S, Beckett NS, Ruth Peters R, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef Nigel S, Beckett NS, Ruth Peters R, Nigel S, Beckett NS, Ruth Peters R, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef
7.
Zurück zum Zitat Lee D, Floras J, Newton G, Austin P, Wang X, Liu P, et al. Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail. 2009;2(6):616–23.PubMedCrossRef Lee D, Floras J, Newton G, Austin P, Wang X, Liu P, et al. Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail. 2009;2(6):616–23.PubMedCrossRef
8.
Zurück zum Zitat Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23(23):1861–6.PubMedCrossRef Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23(23):1861–6.PubMedCrossRef
9.
Zurück zum Zitat The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293.CrossRef The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293.CrossRef
10.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moyé LA, The SAVE Investigators, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669.PubMedCrossRef Pfeffer MA, Braunwald E, Moyé LA, The SAVE Investigators, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669.PubMedCrossRef
11.
Zurück zum Zitat Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001.
12.
Zurück zum Zitat Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.PubMedCrossRef Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.PubMedCrossRef
13.
Zurück zum Zitat Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.PubMedCrossRef Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.PubMedCrossRef
14.
Zurück zum Zitat Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.PubMedCrossRef Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.PubMedCrossRef
15.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709.PubMedCrossRef Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709.PubMedCrossRef
16.
Zurück zum Zitat Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309.PubMedCrossRef Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309.PubMedCrossRef
17.
Zurück zum Zitat •• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11. In this randomized trial of patients with HFrEF with NYHA class II symptoms, the addition of eplerenone to standard therapy reduced mortality by 24%, and reduced hospitalization for HF by 42%.PubMedCrossRef •• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11. In this randomized trial of patients with HFrEF with NYHA class II symptoms, the addition of eplerenone to standard therapy reduced mortality by 24%, and reduced hospitalization for HF by 42%.PubMedCrossRef
18.
Zurück zum Zitat Diez J, Fortuna MA, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol. 1998;13:317–25.PubMedCrossRef Diez J, Fortuna MA, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol. 1998;13:317–25.PubMedCrossRef
19.
Zurück zum Zitat Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207–15.PubMedCrossRef Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207–15.PubMedCrossRef
20.
Zurück zum Zitat Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289–95.PubMedCrossRef Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289–95.PubMedCrossRef
21.
Zurück zum Zitat Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structure, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–96.PubMedCrossRef Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structure, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–96.PubMedCrossRef
22.
Zurück zum Zitat Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433–41.PubMedCrossRef Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433–41.PubMedCrossRef
23.
Zurück zum Zitat Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198–207. Epub 2006 Dec 29.PubMedCrossRef Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198–207. Epub 2006 Dec 29.PubMedCrossRef
24.
Zurück zum Zitat Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115(15):1982–90.PubMedCrossRef Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115(15):1982–90.PubMedCrossRef
25.
Zurück zum Zitat Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54(5):410–8.PubMedCrossRef Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54(5):410–8.PubMedCrossRef
26.
Zurück zum Zitat Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):1214–8.PubMedCrossRef Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):1214–8.PubMedCrossRef
27.
Zurück zum Zitat Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573–81.PubMedCrossRef Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573–81.PubMedCrossRef
28.
Zurück zum Zitat Longobardi G, Ferrara N, Furgi G, Abete P, Rengo F. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2000;36(4):1437–8.PubMedCrossRef Longobardi G, Ferrara N, Furgi G, Abete P, Rengo F. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2000;36(4):1437–8.PubMedCrossRef
29.
Zurück zum Zitat Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37(6):1565–70.PubMedCrossRef Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37(6):1565–70.PubMedCrossRef
30.
Zurück zum Zitat Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.PubMedCrossRef Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.PubMedCrossRef
31.
Zurück zum Zitat Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.PubMedCrossRef Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.PubMedCrossRef
32.
Zurück zum Zitat Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008;10(2):157–63.PubMedCrossRef Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008;10(2):157–63.PubMedCrossRef
33.
Zurück zum Zitat Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659–67.PubMedCrossRef Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659–67.PubMedCrossRef
34.
Zurück zum Zitat ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967–75.CrossRef ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967–75.CrossRef
35.
Zurück zum Zitat U.S. Food and Drug Administration. Aliskiren-containing medications: Drug safety communication—new warning and contraindication. 2012. U.S. Food and Drug Administration. Aliskiren-containing medications: Drug safety communication—new warning and contraindication. 2012.
36.
Zurück zum Zitat Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.PubMedCrossRef Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.PubMedCrossRef
37.
Zurück zum Zitat Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369(9579):2079–87.PubMedCrossRef Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369(9579):2079–87.PubMedCrossRef
38.
Zurück zum Zitat Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.PubMedCrossRef Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.PubMedCrossRef
39.
Zurück zum Zitat • Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55(2):241–8. In this randomized trial of patients with HFpEF and uncontrolled hypertension, improvements in diastolic function as measured by echocardiographic parameters correlated with the degree of blood pressure reduction achieved.PubMedCrossRef • Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55(2):241–8. In this randomized trial of patients with HFpEF and uncontrolled hypertension, improvements in diastolic function as measured by echocardiographic parameters correlated with the degree of blood pressure reduction achieved.PubMedCrossRef
40.
Zurück zum Zitat Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol. 1989;14(4):979–85.PubMedCrossRef Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol. 1989;14(4):979–85.PubMedCrossRef
41.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391.PubMedCrossRef Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391.PubMedCrossRef
42.
Zurück zum Zitat Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60(16):1521–8.PubMedCrossRef Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60(16):1521–8.PubMedCrossRef
43.
Zurück zum Zitat O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439–50.PubMedCrossRef O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439–50.PubMedCrossRef
44.
Zurück zum Zitat • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. In this landmark, randomized trial in patients with resistant hypertension, catheter-based renal denervation therapy resulted in a reduction in blood pressure of 32/12 mmHg at 6 months, with no significant complication or adverse event.PubMedCrossRef • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. In this landmark, randomized trial in patients with resistant hypertension, catheter-based renal denervation therapy resulted in a reduction in blood pressure of 32/12 mmHg at 6 months, with no significant complication or adverse event.PubMedCrossRef
45.
Zurück zum Zitat • Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9. In patients with resistant hypertension, LVH, and diastolic dysfunction treated with catheter-based renal denervation therapy, this study demonstrated significant reduction in LVH and improvement in diastolic function based on echocardiographic parameters.PubMedCrossRef • Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9. In patients with resistant hypertension, LVH, and diastolic dysfunction treated with catheter-based renal denervation therapy, this study demonstrated significant reduction in LVH and improvement in diastolic function based on echocardiographic parameters.PubMedCrossRef
46.
Zurück zum Zitat Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef
47.
Zurück zum Zitat Rosendorff C et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761–88.PubMedCrossRef Rosendorff C et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761–88.PubMedCrossRef
48.
Zurück zum Zitat Pepine CJ et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRef Pepine CJ et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRef
49.
Zurück zum Zitat • Anderson JL et al. ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non–ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123. 2011. This update to ACC-AHA guidelines suggests a blood pressure goal of <140/90 mmHg for based on JNC-7, and <130/80 mmHg for patients with diabetes or chronic kidney disease. • Anderson JL et al. ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non–ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123. 2011. This update to ACC-AHA guidelines suggests a blood pressure goal of <140/90 mmHg for based on JNC-7, and <130/80 mmHg for patients with diabetes or chronic kidney disease.
50.
Zurück zum Zitat Bangalore S et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an International VErapamil SR-trandolapril Study (INVEST) analysis. Eur Heart J. 2009;30:1395–401.PubMedCrossRef Bangalore S et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an International VErapamil SR-trandolapril Study (INVEST) analysis. Eur Heart J. 2009;30:1395–401.PubMedCrossRef
Metadaten
Titel
Treating Hypertension in Patients with Left Ventricular Dysfunction: Hitting the Fairway and Avoiding the Rough
verfasst von
Samuel W. Joffe
Robert A. Phillips
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2013
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-013-0137-9

Weitere Artikel der Ausgabe 2/2013

Current Heart Failure Reports 2/2013 Zur Ausgabe

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S.D. Katz, Section Editor)

Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section Editor)

Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications

Management of Heart Failure (TE Meyer, Section Editor)

Current Status of Cell-Based Therapy for Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section Editor)

Chemohypersensitivity and Autonomic Modulation of Venous Capacitance in the Pathophysiology of Acute Decompensated Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S.D. Katz, Section Editor)

High-Intensity Aerobic Interval Exercise in Chronic Heart Failure

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.